Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Johnson & Johnson (JNJ : NYSE)
 
 • Company Description   
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.

Number of Employees: 138,100

 
 • Price / Volume Information   
Yesterday's Closing Price: $154.22 Daily Weekly Monthly
20 Day Moving Average: 7,501,335 shares
Shares Outstanding: 2,406.07 (millions)
Market Capitalization: $371,064.62 (millions)
Beta: 0.42
52 Week High: $169.99
52 Week Low: $140.68
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 1.64% -3.68%
12 Week -1.24% 6.70%
Year To Date 6.64% 10.81%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
ONE JOHNSON & JOHNSON PLZ
-
NEW BRUNSWICK,NJ 08933
USA
ph: 732-524-0400
fax: 732-214-0332
investor-relations@its.jnj.com http://www.jnj.com
 
 • General Corporate Information   
Officers
J. Duato - Chief Executive Officer;Chairman of the Board
J. J. Wolk - Chief Financial Officer
R. J. Decker Jr. - Controller and Chief Accounting Officer
D. Adamczyk - Director
J. A. Doudna - Director

Peer Information
Johnson & Johnson (AGN.)
Johnson & Johnson (NVS)
Johnson & Johnson (NVO)
Johnson & Johnson (LLY)
Johnson & Johnson (RHHBY)
Johnson & Johnson (JNJ)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: Large Cap Pharma
Sector: Medical
CUSIP: 478160104
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 07/16/25
Share - Related Items
Shares Outstanding: 2,406.07
Most Recent Split Date: 6.00 (2.00:1)
Beta: 0.42
Market Capitalization: $371,064.62 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 3.22%
Current Fiscal Quarter EPS Consensus Estimate: $2.65 Indicated Annual Dividend: $4.96
Current Fiscal Year EPS Consensus Estimate: $10.60 Payout Ratio: 0.49
Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio: 0.03
Estmated Long-Term EPS Growth Rate: 6.23% Last Dividend Paid: 02/18/2025 - $1.24
Next EPS Report Date: 07/16/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 14.54
Trailing 12 Months: 15.35
PEG Ratio: 2.34
Price Ratios
Price/Book: 4.75
Price/Cash Flow: 11.75
Price / Sales: 4.15
EPS Growth
vs. Year Ago Period: 2.21%
vs. Previous Quarter: 35.78%
Sales Growth
vs. Year Ago Period: 2.39%
vs. Previous Quarter: -2.78%
ROE
03/31/25 - 33.46
12/31/24 - 34.24
09/30/24 - 35.45
ROA
03/31/25 - 13.30
12/31/24 - 13.63
09/30/24 - 14.23
Current Ratio
03/31/25 - 1.26
12/31/24 - 1.11
09/30/24 - 1.03
Quick Ratio
03/31/25 - 1.03
12/31/24 - 0.86
09/30/24 - 0.79
Operating Margin
03/31/25 - 27.28
12/31/24 - 27.29
09/30/24 - 28.35
Net Margin
03/31/25 - 24.42
12/31/24 - 18.20
09/30/24 - 19.14
Pre-Tax Margin
03/31/25 - 29.78
12/31/24 - 18.79
09/30/24 - 20.10
Book Value
03/31/25 - 32.46
12/31/24 - 29.69
09/30/24 - 29.14
Inventory Turnover
03/31/25 - 2.27
12/31/24 - 2.26
09/30/24 - 2.29
Debt-to-Equity
03/31/25 - 0.49
12/31/24 - 0.43
09/30/24 - 0.45
Debt-to-Capital
03/31/25 - 32.93
12/31/24 - 30.01
09/30/24 - 30.84
 

Powered by Zacks Investment Research ©